Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Interest & Investment Income: 2016-2024

Historic Interest & Investment Income for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to $41.4 million.

  • Crinetics Pharmaceuticals' Interest & Investment Income rose 13.97% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.2 million, marking a year-over-year increase of 63.37%. This contributed to the annual value of $41.4 million for FY2024, which is 208.39% up from last year.
  • According to the latest figures from FY2024, Crinetics Pharmaceuticals' Interest & Investment Income is $41.4 million, which was up 208.39% from $13.4 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Interest & Investment Income ranged from a high of $41.4 million in FY2024 and a low of $157,000 during FY2021.
  • Its 3-year average for Interest & Investment Income is $19.7 million, with a median of $13.4 million in 2023.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first tumbled by 84.16% in 2021, then spiked by 2,649.68% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Interest & Investment Income (Yearly) stood at $991,000 in 2020, then crashed by 84.16% to $157,000 in 2021, then spiked by 2,649.68% to $4.3 million in 2022, then spiked by 211.23% to $13.4 million in 2023, then spiked by 208.39% to $41.4 million in 2024.